Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure ― What Is the Best Source? ―
نویسندگان
چکیده
منابع مشابه
What Is the Best Research Globally?
Dr. Afshari’s editorial gives insight on human nature (1). Collaborative willingness usually occurs when different sides perceive personal benefit, or when institutions mandate collaboration. This is not unique between higher and lower income countries; many working in global emergency medicine (EM) observe this within wealthier countries. It exists among collaborators in low resource settings....
متن کاملCell therapy for heart failure.
Correspondence: A. Terzic, MD, PhD, Mayo Clinic, 200, First Street SW, Rochester, MN 55905, United States E-mail: [email protected] The pandemic of ischemic heart disease is increasingly recognized as a leading cause of global morbidity. While modern treatment modalities for acute myocardial infarction have reduced early mortality, they have concurrently precipitated a higher incidence of c...
متن کاملCell-Based Therapy of Ischemic Heart Failure
Ischemic heart failure (IHF), heart failure secondary to myocardial infarction, is the number one killer in the US. Despite all the major advances in cardiac interventions, its relevance is on the rise. There is an urgent need for an effective alternative therapy. Stem cells have the potential to ameliorate many chronic illnesses such as IHF. Like any new therapy, several unanswered questions n...
متن کاملPulmonary mucormycosis: what is the best strategy for therapy?
Pulmonary mucormycosis is an uncommon but lifethreatening opportunistic fungal infection.1,2 It typically affects immunocompromised patients, such as recipients of stem cell or organ transplant, and has worse outcomes in those with hematologic malignancy or neutropenia.1,3 In other immunosuppressed states, such as diabetes mellitus, it is less frequent.2,4 In some series the incidence of pulmon...
متن کاملCurrent status of cell-based therapy for heart failure.
In the last two decades, morbidity and mortality of patients with chronic heart failure could be further reduced by improved pharmacological and cardiac device therapies. However, despite these advances, there is a substantial unmet need for novel therapies, ideally specifically addressing repair and regeneration of the damaged or lost myocardium and its vasculature, given the limited endogenou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Journal
سال: 2018
ISSN: 1346-9843,1347-4820
DOI: 10.1253/circj.cj-18-0786